用库尔库加载的纳米结构系统用于治疗莱什曼病:一篇综述
Douglas Dourado1, Thayse Silva Medeiros2, Éverton do Nascimento Alencar3
1Department of Immunology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), 50670-420 Recife, PE, Brazil.
Beilstein journal of nanotechnology
|January 12, 2024
概括
黄素在治疗莱什曼病 - - 一种广泛传播的疾病方面表现有前途. 纳米技术增强了黄素的输送,提高了它对Leishmania寄生虫的有效性.
科学领域:
- 寄生虫学的寄生虫学
- 纳米医学是一种纳米医学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 莱什曼病是一种被忽视的热带疾病,影响全球超过3.5亿人,目前的治疗方法面临有效性和合规性问题.
- 黄是一种来自黄的天然多,对各种*Leishmania*物种表现出杀性活性,可能是由于其抗氧化和抗炎作用.
- 尽管黄素具有潜力,但其临床应用受到生物可用性挑战的限制.
研究的目的:
- 审查黄素载荷纳米载体在治疗莱什曼病的潜力.
- 探索纳米技术如何克服黄素在药物输送中的局限性.
- 突出纳米载体系统的进步,以增强莱什曼杀伤性疗法.
主要方法:
- 文献综述侧重于黄素,纳米载体和莱什曼病治疗.
- 分析研究研究黄素的作用机制和leishmanicidal属性的研究.
- 检查设计用于黄素输送的各种纳米载体系统.
主要成果:
- 纳米载体可以显著改善黄素的稳定性,溶解性和细胞内传递.
- 含有黄素的纳米载体显示出增强的生物活性和对抗Leishmania寄生虫的治疗潜力.
- 纳米技术提供了一种可行的策略,以克服黄素在莱什曼病治疗中的局限性.
结论:
- 载有黄素的纳米载体是开发针对莱什曼病的新有效治疗方法的有希望的策略.
- 基于纳米技术的药物输送系统可以提高黄素等天然化合物的治疗效果.
- 对黄素载荷纳米载体的进一步研究是有必要的,以推进莱什曼病治疗.
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...